ClinicalTrials.gg
RecruitingNCT06189833TAURUSUpdated Apr 23, 2024

Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS

A Phase 2 interventional study of Daratumumab and Bortezomib in Multiple Myeloma, sponsored by Stichting European Myeloma Network. Recruiting at 31 sites in 5 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-04-23.

Sponsored by Stichting European Myeloma Network · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 132 studies testing daratumumab in Multiple Myeloma — 21 open to participants now, 63 under way, 10 of them phase 3. daratumumab · Multiple Myeloma.

Planned enrollment
30th of 132
200 · median 50
Started
2023
with 8 others
Phase 2
73 of 132
7 open now
Primary completion
2024-12
later than 10 of 62 live
Registered
120th of 132
by date
Lead sponsor
4 of 132
Stichting European Myeloma Network

Among the 132 studies testing daratumumab in Multiple Myeloma, this one is the 30th largest by planned enrollment, is one of 9 that started in 2023, is one of 73 in phase 2, reaches primary completion later than 10 of the 62 other live ones, and was the 120th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

21 of the 132 studies testing daratumumab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About daratumumab

daratumumab: first FDA approval 2015 (DARZALEX), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing daratumumab in Multiple Myeloma, or all of them as a file.
02

Study summary

This is a multicenter, single arm, open-label, Phase 2 study in mutiple myeloma with newly diagnosed and treatment-naïve participants for whom high-dose therapy and autologous stem cell transplantation is part of the intended treatment plan. The study is evaluating a technique called Mass Spectrometry Minimal Residual Disease (MS-MRD) using blood samples and compares it with the minimal residual disease (MRD) technique using bone marrow samples.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • MS-MRD
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 70 years of age, inclusive.
  • Must have a new diagnosis of MM as per IMWG criteria.
  • Newly diagnosed and treatment-naïve participants for whom high-dose therapy and stem cell transplantation is part of the intended treatment plan.
  • (ECOG) performance status score of 0, 1, or 2.
  • Clinical laboratory values meeting the required criteria during screening and ≤3 days prior to receiving first study treatment dose.
  • Adequate bone marrow function.
  • Adequate liver function.
  • Adequate renal function.
  • A female of (FOCBP) must have two negative serum or urine pregnancy tests at screening including within 24 hours of the start of study treatment.
  • Willing to practicing at least 1 highly effective method of starting 4 weeks prior to start of study treatment, while receiving study treatment including during any dose interruptions, and for at least 3 months after the last dose of any component of the study treatment.

Exclusion criteria

Exclusion Criteria:

  • Prior or current systemic therapy or for any plasma cell dyscrasia, with the exception of emergency use of a short course (equivalent of dexamethasone 40 mg/day for a maximum 4 days) of before treatment.
  • History of allogenic stem cell transplantation or prior organ transplant requiring therapy.
  • Peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by the National Cancer Institute- (NCI-CTCAE) Version 5.
  • Myelodysplastic syndrome or any within 24 months of signing consent. The only exceptions are malignancies treated within the last 24 months that are considered completely cured.
  • Plasmapheresis ≤28 days of approval.
  • Radiation therapy for treatment of plasmacytoma ≤14 days of approval of enrollment.
  • (FEV1) \<50% of predicted normal.
  • Concurrent medical or psychiatric condition or disease.
  • Myocardial infarction ≤6 months of enrollment, or an unstable or uncontrolled disease/condition related to or affecting cardiac function.
  • Uncontrolled cardiac arrhythmia or (ECG) abnormalities.
  • Allergy, , or intolerance to boron or mannitol, corticosteroids, monoclonal antibodies or human proteins, or the of daratumumab, lenalidomide, bortezomib or dexamethasone.
  • Pregnant or breast-feeding females
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    D-VRd + ASCT + DVRD

    Participants will receive daratumumab, bortezomib, lenalidomide and dexamethasone (DVRD) for 4 induction cycles prior to and 2 consolidation cycles following autologous stem cell transplantation. Daratumumab subcutaneously (SC), 1800 mg on days 1, 8, 15 and 22 of cycle 1 and 2, on days 1 and 15 of cycle 3-6 Bortezomib SC 1.3mg/m2 on days 1, 8, 15, 22 of cycle 1-6 Lenalidomide orally 25 mg once daily on days 1-21 of cycle 1-6 Dexamethasone 20 mg once daily on days 1, 2, 8, 9, 15, 16, 22 and 23 of cycle 1-6

    Drug: Daratumumab · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone

Interventions

  • Daratumumab will be administered via a subcutaneous injection (SC)

    Also known as: JNJ-54767414

  • Bortezomib will be administered via a subcutaneous injection (SC)

    Also known as: Velcade

  • Lenalidomide will be administered orally

  • Dexamethasone will be administered orally

06

What researchers measure

Primary outcomes

  1. Proportion (%) of agreement and disagreement in the MRD measurements in BM (by NGS-MRD) and in the MRD measurements in peripheral blood (by MS-MRD) at post-consolidation.

    The proportion (%) of agreement will be defined as the total number of concordant cases (i.e., MRD-positive by both techniques, MRD-negative by both techniques) versus the total number of cases with available results.

    Time frame: Up to 12 months

Secondary outcomes

  1. Proportion (%) of agreement and disagreement in the MRD measurements in BM (by NGS-MRD) and in the MRD measurements in peripheral blood (by MS-MRD) at post-induction.

    The proportion (%) of agreement will be defined as the total number of concordant cases (i.e., MRD-positive by both techniques, MRD-negative by both techniques) versus the total number of cases with available results.

    Time frame: Up to 4 months and 2 weeks

  2. Proportion (%) of agreement and disagreement in the MRD measurements in BM (by NGF-MRD) and in the MRD measurements in peripheral blood (by MS-MRD) at post-induction and post-consolidation.

    The proportion (%) of agreement will be defined as the total number of concordant cases (i.e., MRD-positive by both techniques, MRD-negative by both techniques) versus the total number of cases with available results.

    Time frame: Up to 12 months

  3. Proportion (%) of agreement and disagreement in the MRD measurements in BM by NGF-MRD and NGS-MRD at post-induction and post-consolidation.

    The proportion (%) of agreement will be defined as the total number of concordant cases (i.e., MRD-positive by both techniques, MRD-negative by both techniques) versus the total number of cases with available results.

    Time frame: Up to 12 months

  4. MRD negativity rate BM-MRD and PB-MRD

    To evaluate the MRD negativity rate achieved at any time up to the end of consolidation with BM based MRD techniques and with the MS-MRD technique

    Time frame: Up to 12 months

  5. ORR, VGPR or better, CR or better, sCR at post-induction, post-transplant, post-consolidation and overall.

    ORR will be defined as the percentage of participants achieving confirmed PR or better (i.e., PR+VGPR+CR+sCR). The number and percentage of participants achieving ORR, VGPR or better, CR or better and sCR will be presented, post-induction, post-consolidation, post-transplant and overall.

    Time frame: Up to 12 months

  6. Effect of cytogenetic abnormalities (presence or not), R-ISS (1, 2 or 3), CTCs (number of cells per ml) on likelihood to develop MRD-negative disease (with MS, NGS and NGF) and the agreement between the different techniques.

    Binary logistic regression will be used to identify factors associated with post-induction and post-consolidation MRD status (negative or positive) (as defined with NGS-MRD; NGF-MRD; MS-MRD; the most conservative method), in the MRD-evaluable Analysis Set. Odds ratios and respective 95% CIs will be estimated from univariable and multivariable models.

    Time frame: Up to 12 months

07

Study locations

19 of 31 sites recruiting
  • Innsbruck Medical University
    Innsbruck, Austria
    Not yet recruiting
    • Willenbacher · Contact
  • Ordensklinikum Linz
    Linz, Austria
    Recruiting
    • Strassl · Contact
  • Clinic Ottakring
    Vienna, Austria
    Not yet recruiting
    • Schreder · Contact
  • Medical University of Vienna
    Vienna, Austria
    Not yet recruiting
    • Krauth · Contact
  • Universitätsklinikum Hamburg - Eppendorf
    Hamburg, Germany
    Recruiting
    • Weisel · Contact
  • Klinikum rechts der Isar (MRI) der Technischen Universität München Department of Internal Medicine III (Hematology/Oncology) Munchen
    München, Germany
    Not yet recruiting
    • Basserman · Contact
  • University Hospital of Alexandroupolis
    Alexandroupolis, Greece
    Recruiting
    • Spanoudakis · Contact
  • Alexandra General Hospital -Department of Clinical Therapeutics N.K. Univ. of Athens
    Athens, Greece
    Recruiting
    • Evangelos Terpos · Contact
  • St Savvas Cancer Hospital
    Athens, Greece
    Recruiting
    • Pouli · Contact
  • Theagenion Cancer Hospital
    Thessaloníki, Greece
    Recruiting
    • Katodritou · Contact
  • AOU Ospedali Riuniti di Ancona
    Ancona, Italy
    Recruiting
    • Offidani · Contact
  • ASST Papa Giovanni XXIII Hospital
    Bergamo, Italy
    Recruiting
    • Rambaldi · Contact
  • A.O.U. di Bologna - Policlinico S. Orsola Malpighi
    Bologna, Italy
    Not yet recruiting
    • Zamagni · Contact
  • A.O.Spedali Civili di Brescia
    Brescia, Italy
    Recruiting
    • Belotti · Contact
  • A.O.U. Careggi - Firenze
    Firenze, Italy
    Recruiting
    • Antonioli · Contact
  • A.O.U. Policlinico S. Martino - Ematologia
    Genova, Italy
    Not yet recruiting
    • Aquino · Contact
    • Aquino · Principal investigator
  • Novara Hospital
    Novara, Italy
    Recruiting
    • Margiotta Casaluci · Contact
  • Policlinico S. Matteo Fondazione IRCCS - Pavia
    Pavia, Italy
    Recruiting
    • Mangiacavalli · Contact
  • AUSL-IRCCS di Reggio Emilia Arcispedale S. Maria Nuova
    Reggio Emilia, Italy
    Recruiting
    • Gamberi · Contact
  • Ospedale "Infermi" di Rimini
    Rimini, Italy
    Recruiting
    • Tosi · Contact
  • Ematologia IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo
    San Giovanni Rotondo, Italy
    Recruiting
    • Falcone · Contact
  • A.O. S. Santa Maria Hospital Institute of Oncohematology Terni
    Terni, Italy
    Not yet recruiting
    • Liberati · Contact
  • A.O.U. Città della Salute e della Scienza di Torino - SC Ematologia U
    Torino, 10126, Italy
    Recruiting
    • Mina · Contact
  • Ospedale S. Maria della Misericordia di Udine
    Udine, Italy
    Not yet recruiting
    • Patriarca · Contact
  • Amsterdam Medical Center
    Amsterdam, Netherlands
    Not yet recruiting
    • van der Donk · Contact
  • Rijnstate
    Arnhem, Netherlands
    Recruiting
    • Van der Spek · Contact
  • Amphia ziekenhuis
    Breda, Netherlands
    Not yet recruiting
    • van der Klift · Contact
    • van der Klift · Principal investigator
  • University Medical Center Groningen
    Groningen, Netherlands
    Not yet recruiting
    • Roeloffzen · Contact
  • Dijklander ziekenhuis
    Purmerend, Netherlands
    Recruiting
    • Klerk · Contact
  • Erasmus University Medical Center Rotterdam
    Rotterdam, Netherlands
    Not yet recruiting
    • Wester · Contact
  • Maasstad Ziekenhuis
    Rotterdam, Netherlands
    Recruiting
    • Sprenger · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Dec 2024, 13 months after the start.

Of 411 non-industry phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's planned 13 months is below that.

Counting every sponsor, half of 504 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2023
First posted
Jan 5, 2024
StartActual
Nov 23, 2023
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2025
Last update
Apr 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06189833
Lead sponsor
Stichting European Myeloma Network
Responsible party
Sponsor
First posted
Jan 5, 2024
Start date
Nov 23, 2023
Primary completion
Dec 2024 (estimated)
Completion
Dec 2025 (estimated)
Last update
Apr 23, 2024

Study contacts

Rosita Ghiraw-Visser
Contact
rosita.ghiraw@emn.org
+31 10 703 31 23

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Daratumumab · Bortezomib · Lenalidomide · Dexamethasone

Start the discussion